2.07

2.36% -0.05

After Hours: 2.17 0.10 +4.83%

Prelude Therapeutics Inc (PRLD)

Overview News Price History Option Chain Financials Discussions Forecast

Prelude Therapeutics Inc stock is traded at $2.07, with a volume of 166.16K. It is down -2.36% in the last 24 hours and down -60.19% over the past month. Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

Previous Close:

$2.12

Open:

$2.1

24h Volume:

166.16K

Relative Volume:

0.62

Market Cap:

$112.80M

Revenue:

Net Income/Loss:

$-121.83M

P/E Ratio:

-0.9539

EPS:

-2.17

Net Cash Flow:

$-110.58M

1W Performance:

-12.66%

1M Performance:

-60.19%

6M Performance:

-56.33%

1Y Performance:

-33.01%

1-Day Range:

$2.00

$2.16

1-Week Range:

$1.98

$2.448

52-Week Range:

$1.66

$6.80

Prelude Therapeutics Inc Stock (PRLD) Company Profile

Name

Prelude Therapeutics Inc

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

(302) 467-1280

Address

175 INNOVATION BOULEVARD, WILMINGTON

Employee

128

Twitter

Next Earnings Date

2024-10-30

Latest SEC Filings

PRLD's Discussions on Twitter

Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-21-22	Downgrade	BofA Securities	Neutral → Underperform
Sep-09-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jul-29-22	Initiated	Jefferies	Buy
Mar-15-22	Downgrade	BofA Securities	Buy → Neutral
Feb-28-22	Downgrade	Barclays	Overweight → Equal Weight
Oct-08-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jul-27-21	Upgrade	BofA Securities	Neutral → Buy
Apr-26-21	Initiated	H.C. Wainwright	Buy
Mar-09-21	Initiated	Barclays	Overweight
Nov-20-20	Downgrade	BofA Securities	Buy → Neutral
Oct-20-20	Initiated	BofA Securities	Buy
Oct-20-20	Initiated	Goldman	Neutral
Oct-20-20	Initiated	Morgan Stanley	Equal-Weight

View All

Prelude Therapeutics Inc Stock (PRLD) Latest News

Sep 29, 2024

Invesco S&P SmallCap Materials ETF (NASDAQ:PSCM) Short Interest Up 22.6% in September - Defense World

Sep 29, 2024

First Trust NASDAQ ABA Community Bank Index Fund (NASDAQ:QABA) Short Interest Update - Defense World

Sep 29, 2024

RF Acquisition Corp. (NASDAQ:RFAC) Short Interest Update - Defense World

Sep 29, 2024

Axa S.A. Acquires 1,964 Shares of West Pharmaceutical Services, Inc. (NYSE:WST) - Defense World

Sep 29, 2024

Sep 23, 2024

FDA Issues Draft Guidance on Multiregional Clinical Trials in Oncology - MyChesCo

Sep 23, 2024

19 Sundance Movies to Watch Before Seeing These Filmmakers’ New Fall 2024 Releases - Sundance Institute

Sep 20, 2024

First Taste: At Prelude, Southern-inspired flavors get the fine-dining spotlight. - 7x7

Sep 20, 2024

Prelude Therapeutics (NASDAQ:PRLD) Upgraded to Strong-Buy by HC Wainwright - MarketBeat

Sep 20, 2024

Sep 19, 2024

Aclaris Therapeutics Launches Phase 2a Trial for ATI-2138 in Atopic Dermatitis - MyChesCo

Sep 19, 2024

Sep 18, 2024

Data clang on Street for Prelude but SMARCA2 overtures continue - BioWorld Online

Sep 18, 2024

Healthy Upside Potential: Prelude Therapeutics Inc (PRLD) - SETE News

Sep 18, 2024

Passage Bio Shares Promising Data on PBFT02 for Frontotemporal Dementia - MyChesCo

Sep 18, 2024

Sep 17, 2024